When you look at the sheer numbers, the US Bone Density Test Market is witnessing a quiet revolution through "opportunistic screening." In 2026, the market is no longer solely reliant on patients being specifically referred for a DEXA scan. Instead, AI-powered software is now being used to analyze standard CT scans and X-rays—originally taken for unrelated issues like abdominal pain—to extract bone mineral density (BMD) data. This allows clinicians to identify at-risk patients who are "invisible" to traditional screening pathways. In the U.S. alone, this technology is tapping into a massive pool of potential diagnoses, significantly boosting the demand for integrated software and diagnostic services.

This shift toward automated analytics is a major driver for the global Bone Density Test Market, which is projected to reach approximately $1.6 billion in 2026. By removing the "referral barrier," healthcare systems are finding they can capture data on bone loss much earlier. For the market, this means a shift in revenue:

• Hardware: Increased demand for AI-compatible CT and X-ray systems.

• Software: A surge in SaaS (Software as a Service) subscriptions for bone health analytics.

• Consulting: Higher demand for specialized radiologists to interpret AI-generated bone health reports.